Maarten Bijlsma (re)joins GRIP
Welcome to Dr. Maarten J. Bijlsma, our new tenure track assistant professor of precision drug therapy at the research unit PharmacoTherapy, -Epidemiology & -Economics (PTEE) of the Groningen Research Institute of Pharmacy (GRIP). Before joining us, Maarten was deputy head of the Laboratory of Population Health of the Max Planck Institute for Demographic Research in Germany. He received his doctorate in Pharmacoepidemiology in 2016 from GRIP, so he is now returning home!
Maarten is an applied statistician and pharmacoepidemiologist whose research focuses on counterfactual causal inference in observational settings. At PTEE, Maarten intends to apply and further develop techniques at the intersection of pharmacoepidemiology, statistics, causal inference, and machine learning. With these techniques he hopes to gain new insights that will contribute to the ambitious goals of precision medicine, further optimizing drug therapy and patient outcomes.
In the past years, Maarten has made a number of contributions to the g-formula, a very flexible statistical method for modelling dynamic treatment regimes. His research is published in Epidemiology, International Journal of Epidemiology (upcoming), Journal of the Royal Statistical Society, The Lancet: Infectious Diseases, Social Science & Medicine, and many others.

Last modified: | 21 May 2024 11.14 a.m. |
More news
-
24 March 2025
UG 28th in World's Most International Universities 2025 rankings
The University of Groningen has been ranked 28th in the World's Most International Universities 2025 by Times Higher Education. With this, the UG leaves behind institutions such as MIT and Harvard. The 28th place marks an increase of five places: in...
-
05 March 2025
Women in Science
The UG celebrates International Women’s Day with a special photo series: Women in Science.
-
16 December 2024
Jouke de Vries: ‘The University will have to be flexible’
2024 was a festive year for the University of Groningen. In this podcast, Jouke de Vries, the chair of the Executive Board, looks back.